Table 5:
Functional Outcomes After TAVI or SAVR in Low-Risk Patients: As-Treated Analysis
| Author, Year | NYHA Functional Class I/II Among Survivors, % | Quality of Life, SF-12, Mean (SD) | |
|---|---|---|---|
| TF-TAVI vs. SAVR | |||
|
Baseline Thyregod et al, 201522 |
TAVI: 52.5 SAVR: 54.9 |
NA | |
|
3 Months Thyregod et al, 201522 |
TAVI: 94.8 SAVR: 96.6 |
||
|
1 Year Thyregod et al, 201522 |
TAVI: 96.9 SAVR: 96.7 |
||
| TA-TAVI vs. SAVR | |||
|
Baseline Nielsen et al, 201223 |
TAVI: 16 SAVR: 20 |
Physical TAVI: 35 (10) SAVR: 37 (12) P = .48 |
Mental TAVI: 47 (10) SAVR: 46 (17) P = .66 |
|
3 Months Nielsen et al, 201223 |
TAVI: 26 SAVR: 32 P = .16 |
Physical TAVI: 42 (14) SAVR: 43 (15) P = .91 |
Mental TAVI: 53 (14) SAVR: 50 (17) P = .44 |
Abbreviations: NA, not available; NYHA, New York Heart Association; SD, standard deviation; SF-12, 12-item Short Form questionnaire; SAVR, surgical aortic valve replacement; TA, transapical; TAVI, transcatheter aortic valve implantation; TF, transfemoral.